Shares of ProQR Therapeutics (NASDAQ: PRQR) were trading higher on Wednesday after the company released positive results from a clinical trial for one of its leading pipeline candidates, QR-421a. The biotech is also benefiting from bullish commentary from a Wall Street analyst. As of 1:07 p.m. EDT, ProQR stock was up by 8% after rising by as much as 13.5% earlier today.
QR-421a is an experimental treatment for Usher syndrome, a rare disorder that, among other things, can cause loss of vision. In a phase 1/2 clinical trial for QR-421a, the treatment was well tolerated by patients and produced improvement in several measures of vision, including visual acuity, visual field, and more.
Aniz Girach, chief medical officer of ProQR Therapeutics, said, "With just a single dose, QR-421a demonstrated clinical proof of concept with benefit observed in treated eyes compared to the untreated eyes in multiple concordant measures of vision."
For further details see:
Why ProQR Therapeutics Stock Is Popping Today